Pharmacist Intervention to Improve Smoking Cessation

NCT ID: NCT06943287

Last Updated: 2026-01-26

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-11
• Study Completion Date: 2026-06-30

Brief Summary

The goal of this study is to assess the effectiveness of a remote pharmacist intervention to help smokers quit.

The main questions it aims to answer are:

• Will smokers being screened for lung cancer with low-radiation-level chest computed tomography (CT) be willing to participate in this study and talk to the pharmacist about smoking cessation?
• Will those in the intervention group be more likely to report smoking cessation than those in the control group.

Participants in the intervention group will be asked to complete a baseline survey; speak with a pharmacist via phone call at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks; and complete an exit survey.

Participants in the control group will be asked to complete a baseline survey and an exit survey.

Conditions

Smoking Cessation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Pharmacist Intervention Group

Group Type: EXPERIMENTAL

Pharmacist Intervention

Intervention Type: BEHAVIORAL

If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.

Control Group

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Pharmacist Intervention

If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Current smoker
• Current patient in the Lung Cancer Screening Program

Exclusion Criteria

• Unable to speak/read English
• Unable to provide their own written informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Iowa

OTHER

Sponsor Role: lead

Responsible Party

Jacob E. Simmering

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jacob E Simmering, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Iowa

Locations

University of Iowa Health Care

Iowa City, Iowa, United States

Countries

United States

Other Identifiers

202411248

Identifier Type: -

Identifier Source: org_study_id